Tesaro informs doctors of hypersensitivity risks with Varubi

Tesaro Inc. (NASDAQ:TSRO) issued a Dear Health Care Provider letter for Varubi rolapitant IV (SCH 619734)

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE